SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS

The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disea...

Full description

Saved in:
Bibliographic Details
Main Authors BEYER, Kristin, FREUDENBERGER, Till, LINDNER, Niels, MEIBOM, Daniel, CANCHO GRANDE, Yolanda, ZUBOV, Dmitry, STEFAN, Eric, WASNAIRE, Pierre, MATHAR, Ilka, KRAINZ, Tanja, ELOWE, Nadine, SANCHEZ, Guzman, XING, Yi, JOHANNES, Sarah, Anna, Liesa, BROCKSCHNIEDER, Damian, MENSHYKAU, Dzianis, KLAR, Jürgen, MACDONALD, Bryan
Format Patent
LanguageEnglish
French
German
Published 21.09.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The application relates to substituted hydantoinamides of formula (I) as ADAMTS7 antagonists, to processes for their preparation, their use alone or in combination for the treatment or prophylaxis of diseases, in particular of cardiovascular diseases, including atherosclerosis, coronary artery disease (CAD), peripheral vascular disease (PAD), arterial occlusive disease or restenosis after angioplasty.R 1 is hydrogen, alkyl, cycloalkyl, 5- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl or phenyl; R 2 is hydrogen or alkyl; A is 5-membered heteroaryl; Z is 6- to 10-membered aryl or 5- to 10-membered heteroaryl; all groups being optionally substituted.
Bibliography:Application Number: EP20200803571